PURE / PURE Bioscience, Inc. - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 PURE BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission Fi

Securities PURCHASE AGREEMENT

Exhibit 10.1 Securities PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 30, 2026, among Pure Bioscience, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as s

PURE Bioscience Reports Fiscal Second Quarter 2026 Financial Results

Exhibit 99.1 PURE Bioscience Reports Fiscal Second Quarter 2026 Financial Results EL CAJON, Calif. – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2026. Summary of Results – Fiscal Second Quarter Operations ● Net pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 PURE BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 PURE BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2025 PURE BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2025 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results

PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results EL CAJON, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 PURE BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE Bioscience, Inc. Announces Leadership Promotions

Exhibit 99.1 PURE Bioscience, Inc. Announces Leadership Promotions El CAJON, CA – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE” or the “Company”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company has appointed Jeff Kitchell as President, in addition to his ongoing responsibilities as Corporate Secretary, and Dolana Blount as Vice Presi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number. 001-14468 PURE Bioscience, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 PURE BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE Bioscience Reports Fiscal 2025 Financial Results

Exhibit 99.1 PURE Bioscience Reports Fiscal 2025 Financial Results El CAJON, CA – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2025. Summary of Results – Year-End Operations ● Net product sales were $2,198,000 and $1,955,000 fo

DESCRIPTION OF CAPITAL STOCK

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK General Pure Bioscience, Inc. (“we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.01 par value per share. The following information describes our capital stock, as well as certain provisions of our Certificate of Incorporation and Bylaws. The summary does n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number: 001-14468 PURE Bioscience, Inc. (Exact name of registrant as sp

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fil

PURE Bioscience Reports Fiscal Third Quarter 2025 Financial Results

Exhibit 99.1 PURE Bioscience Reports Fiscal Third Quarter 2025 Financial Results EL CAJON, Calif. – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2025. Summary of Results of Operations – Fiscal Third Quarter ● Net prod

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as s

PURE Bioscience Reports Fiscal Second Quarter 2025 Financial Results

Exhibit 99.1 PURE Bioscience Reports Fiscal Second Quarter 2025 Financial Results EL CAJON, Calif. – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2025. Summary of Results – Fiscal Second Quarter Operations ● Net pr

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2025 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE Bioscience Reports Fiscal First Quarter 2025 Financial Results

Exhibit 99.1 PURE Bioscience Reports Fiscal First Quarter 2025 Financial Results EL CAJON, Calif. - (December 16, 2024) – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2024. Summary of Results – Fiscal First Quarter

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Description of Capital Stock

EX-4.3 2 ex4-3.htm Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK General Pure Bioscience, Inc. (“we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.01 par value per share. The following information describes our capital stock, as well as certain provisions of our Certificate of Incorporation and Bylaws.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE Bioscience Reports Fiscal 2024 Financial Results

Exhibit 99.1 PURE Bioscience Reports Fiscal 2024 Financial Results El CAJON, CA – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2024. Summary of Results – Year-End Operations ● Net product sales were $1,955,000 and $1,871,000 fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number. 001-14468 PURE Bioscience, Inc. (Exact

Form of Note Purchase Agreement.

Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (“Agreement”) is made as of September 16, 2024, by and among Pure Bioscience, Inc., a Delaware corporation (the “Company”), and the lenders (each, a “Lender” and collectively, the “Lenders”) named on Schedule 1 attached hereto (the “Schedule of Lenders”). Capitalized terms not otherwise defined in this Agreement shall have the meani

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commissio

Form of Convertible Promissory Note.

Exhibit 4.1 EXHIBIT A THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY

2024 Equity Incentive Plan.

Exhibit 99.1 Pure Bioscience, Inc. 2024 Equity Incentive Plan Pure Bioscience, Inc. 2024 Equity Incentive Plan ARTICLE 1. INTRODUCTION. The Board adopted the Plan on December 21, 2023, subject to the approval of the Company’s stockholders. No Awards may be granted prior to the Effective Date. The Plan replaces the Company’s Amended and Restated 2007 Equity Incentive Plan and the Amended and Restat

Description of Capital Stock.

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK General Pure Bioscience, Inc. (“we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.01 par value per share. The following information describes our capital stock, as well as certain provisions of our Certificate of Incorporation and Bylaws. The summary does n

As filed with the Securities and Exchange Commission on August 15, 2024

As filed with the Securities and Exchange Commission on August 15, 2024 Registration No.

Calculation of Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PURE Bioscience, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 PURE BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

Certificate of Amendment.

Exhibit 3.1

PURE Bioscience Reports Fiscal Third Quarter 2024 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal Third Quarter 2024 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions EL CAJON, Calif. - (June 14, 2024) – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third qu

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number: 001-14468 PURE Bioscience, Inc. (Exact name of registrant as sp

PURE Bioscience Appoints Darin Zehr to Board of Directors

Exhibit 99.1 PURE Bioscience Appoints Darin Zehr to Board of Directors EL CAJON, Calif. - (May 6, 2024) – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported the appointment of Darin Zehr to its Board of Directors, effective as of May 1, 2024. Mr. Zehr joins as an independent director a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission File

Form of Note Purchase Agreement.

Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (“Agreement”) is made as of March 22, 2024, by and among Pure Bioscience, Inc., a Delaware corporation (the “Company”), and the lenders (each, a “Lender” and collectively, the “Lenders”) named on Schedule 1 attached hereto (the “Schedule of Lenders”). Capitalized terms not otherwise defined in this Agreement shall have the meanings

Form of Convertible Promissory Note (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on March 27, 2024).

Exhibit 4.1 EXHIBIT A THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

PURE Bioscience Reports Fiscal Second Quarter 2024 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal Second Quarter 2024 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions EL CAJON, Calif. - (March 18, 2024) – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 PURE BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as s

PURE Bioscience Reports Fiscal First Quarter 2024 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal First Quarter 2024 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions El Cajon, CA (December 14, 2023) – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quar

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

Description of Capital Stock

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK General Pure Bioscience, Inc. (“we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.01 par value per share. The following information describes our capital stock, as well as certain provisions of our Certificate of Incorporation and Bylaws. The summary does n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file No. 001-14468 PURE Bioscience, Inc. (Exact name

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE Bioscience Reports Fiscal 2023 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal 2023 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions El CAJON, CA (October 30, 2023) – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2023.

Form of Convertible Promissory Note (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the SEC on July 10, 2023).

Exhibit 4.1 EXHIBIT A THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY

Form of Note Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on July 10, 2023).

Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (“Agreement”) is made as of June 30, 2023, by and among Pure Bioscience, Inc., a Delaware corporation (the “Company”), and the lenders (each, a “Lender” and collectively, the “Lenders”) named on Schedule 1 attached hereto (the “Schedule of Lenders”). Capitalized terms not otherwise defined in this Agreement shall have the meanings a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 PURE BIOSCIENCE, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission File

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as spe

PURE Bioscience Reports Fiscal 2023 Third Quarter And Nine-Month Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal 2023 Third Quarter And Nine-Month Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Solutions RANCHO CUCAMONGA, CA (June 14, 2023) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-mon

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 PURE BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 PURE BIOSCIENCE, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

PURE Bioscience Reports Fiscal 2023 Second Quarter And Six-Month Financial Results

Exhibit 99.1 PURE Bioscience Reports Fiscal 2023 Second Quarter And Six-Month Financial Results RANCHO CUCAMONGA, CA (March 17, 2023) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter and six-month period ended January 31, 2023. Q2: Summary of Results of Operations ●

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as s

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 08, 2023 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE Bioscience Reports Fiscal First Quarter 2023 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal First Quarter 2023 Financial Results Update on Business and PURE?s SDC-Based Antimicrobial Food Safety Solutions RANCHO CUCAMONGA, CA (December 14, 2022) ? PURE Bioscience, Inc. (OTCQB: PURE) (?PURE,? the ?Company? or ?we?), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as s

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2022 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file No. 001-14468 PURE Bioscience, Inc. (Exact name

PURE Bioscience Reports Fiscal 2022 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal 2022 Financial Results Update on Business and PURE?s SDC-Based Antimicrobial Food Safety Solutions RANCHO CUCAMONGA, CA (October 28, 2022) ? PURE Bioscience, Inc. (OTCQB: PURE) (?PURE,? the ?Company? or ?we?), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 3

Description of Capital Stock

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK General Pure Bioscience, Inc. (?we,? ?us,? and ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.01 par value per share. The following information describes our capital stock, as well as certain provisions of our Certificate of Incorporation and Bylaws. The summary does n

Form of Securities Purchase Agreement.

Exhibit 10.1 Securities PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 15, 2022, among Pure Bioscience, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as spe

PURE Bioscience Reports Fiscal 2022 Third Quarter And Nine-Month Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal 2022 Third Quarter And Nine-Month Financial Results Update on Business Segments and PURE?s SDC-Based Antimicrobial Solutions RANCHO CUCAMONGA, CA (June 14, 2022) ? PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-mon

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fil

PURE Bioscience Reports Fiscal 2022 Second Quarter And Six-Month Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal 2022 Second Quarter And Six-Month Financial Results Update on Business Segments and PURE?s SDC-Based Antimicrobial Food Safety Solutions RANCHO CUCAMONGA, CA (March 15, 2022) ? PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as s

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 03, 2022 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

As filed with the Securities and Exchange Commission on January 26, 2022

As filed with the Securities and Exchange Commission on January 26, 2022 Registration No.

Amended and Restated 2017 PURE Bioscience Equity Incentive Plan

Exhibit 99.1 AMENDED AND RESTATED PURE BIOSCIENCE, INC. 2017 EQUITY INCENTIVE PLAN This Amended and Restated PURE Bioscience 2017 Equity Incentive Plan (the ?Plan?) was originally adopted in January 2018. This amendment and restatement of the Plan was approved by the Board of Directors of the Company on November 17, 2020, and shall become effective on January 20, 2020 (the date of such approval, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

PURE Bioscience Reports Fiscal First Quarter 2022 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal First Quarter 2022 Financial Results Update on Business and PURE?s SDC-Based Antimicrobial Food Safety Solutions RANCHO CUCAMONGA, CA (December 15, 2021) ? PURE Bioscience, Inc. (OTCQB: PURE) (the ?Company,? ?PURE? or ?we?), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as s

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file No. 001-14468 PURE Bioscience, Inc. (Exact name

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE Bioscience Reports Fiscal 2021 Financial Results Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal 2021 Financial Results Update on Business and PURE?s SDC-Based Antimicrobial Food Safety Solutions RANCHO CUCAMONGA, CA (October 28, 2021) ? PURE Bioscience, Inc. (OTCQB: PURE) (the ?Company,? ?PURE? or ?we?), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 3

Description of Capital Stock

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK General Pure Bioscience, Inc. (?we,? ?us,? and ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.01 par value per share. The following information describes our capital stock, as well as certain provisions of our Certificate of Incorporation and Bylaws. The summary does n

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 19, 2021 PURE BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as

PURE Bioscience Reports Fiscal 2021 Third Quarter And Nine-Month Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Food Safety Solutions

PURE Bioscience Reports Fiscal 2021 Third Quarter And Nine-Month Financial Results Update on Business Segments and PURE?s SDC-Based Antimicrobial Food Safety Solutions RANCHO CUCAMONGA, CA (June 14, 2021) ? PURE Bioscience, Inc.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fil

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2021 PURE BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission File Num

Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on May 19, 2021).

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF PURE BIOSCIENCE, INC., a Delaware Corporation Pure Bioscience, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify that: 1. Paragraph (A) of Article IV of the Corporation?s Certificate of Incorporation is hereby amended and restated

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant

PURE Bioscience Reports Fiscal 2021 Second Quarter And Six-Month Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal 2021 Second Quarter And Six-Month Financial Results Update on Business Segments and PURE?s SDC-Based Antimicrobial Food Safety Solutions RANCHO CUCAMONGA, CA (March 15, 2021) ? PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarte

Submission of Matters to a Vote of Security Holders -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant

PURE Bioscience Reports Fiscal First Quarter 2021 Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1 PURE Bioscience Reports Fiscal First Quarter 2021 Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Food Safety Solutions RANCHO CUCAMONGA, CA (December 15, 2020) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended Octob

Results of Operations and Financial Condition, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

-

As filed with the Securities and Exchange Commission on October 19, 2020 Registration No.

PURE Bioscience Reports Fiscal 2020 Financial Results Achieves Annual Profit for First Time in Company’s History on Revenue of $6.9 million

Exhibit 99.1 PURE Bioscience Reports Fiscal 2020 Financial Results Achieves Annual Profit for First Time in Company’s History on Revenue of $6.9 million RANCHO CUCAMONGA, CA (October 8, 2020) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2020. Summary of Res

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file No. 001-14468 PURE Bioscience, Inc. (Exact

Description of Capital Stock

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK General Pure Bioscience, Inc. (“we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.01 par value per share. The following information describes our capital stock, as well as certain provisions of our Certificate of Incorporation and Bylaws. The summary does n

Results of Operations and Financial Condition, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2020 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission F

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED November 4, 2019) PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated November 4, 2019 (the “Prospectus”), relating

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fil

PURE Bioscience Reports Fiscal 2020 Third Quarter and Nine-Month Financial Results Achieves Quarterly Profit for First Time in Company’s History

Exhibit 99.1 PURE Bioscience Reports Fiscal 2020 Third Quarter and Nine-Month Financial Results Achieves Quarterly Profit for First Time in Company’s History RANCHO CUCAMONGA, CA (June 11, 2020) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2020 an

PURE Bioscience Announces Exclusive Distribution Partnership with PSSI

Exhibit 99.1 PURE Bioscience Announces Exclusive Distribution Partnership with PSSI RANCHO CUCAMONGA, CA (May 21, 2020) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antiviral/antibacterial, and Packers Sanitation Services, Inc. (PSSI), have entered into an exclusive multi-year distribution partnership. Under the terms of the agreement, PS

Supply and License Agreement, effective May 1, 2020, by and between Pure Bioscience, Inc. and Packers Sanitation Services, Inc.

Exhibit 10.1 * CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN EXCLUDED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. Supply and License Agreement (With Sub-License & Packaging Rights) This SUPPLY AND LICENSE AGREEMENT (this “Agreement”) is entered into as of May 1, 2020 (“Ef

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission File

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED November 4, 2019) PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated November 4, 2019 (the “Prospectus”), relating

PURE Bioscience Reports Fiscal 2020 Second Quarter and Six-Month Financial Results Update on SDC-Based Antimicrobial Food Safety Solutions

PURE Bioscience Reports Fiscal 2020 Second Quarter and Six-Month Financial Results Update on SDC-Based Antimicrobial Food Safety Solutions RANCHO CUCAMONGA, CA (March 12, 2020) – PURE Bioscience, Inc.

PURE / PURE Bioscience 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

Form of Securities Purchase Agreement

Exhibit 10.1 Securities PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 9, 2020, among Pure Bioscience, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE / PURE Bioscience DEF 14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED November 4, 2019) PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated November 4, 2019 (the “Prospectus”), relating

PURE Bioscience Reports Fiscal 2020 Q1 Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Food Safety Solutions

Exhibit 99.1  PURE Bioscience Reports Fiscal 2020 Q1 Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Food Safety Solutions RANCHO CUCAMONGA (Dec 13, 2019) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2019. Q1 -

PURE / PURE Bioscience 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

Letter of Mayer Hoffman McCann P.C. dated November 18, 2019.

Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE / PURE Bioscience POS AM - -

As filed with the Securities and Exchange Commission on October 31, 2019 Registration No.

PURE / PURE Bioscience 10-K - Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file No. 001-14468 PURE Bioscience, Inc. (Exact

PURE Bioscience Reports Fiscal 2019 Year-End Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Food Safety Solutions

PURE Bioscience Reports Fiscal 2019 Year-End Financial Results Update on Business Segments and PURE’s SDC-Based Antimicrobial Food Safety Solutions SAN DIEGO, CA (Oct 29, 2019) – PURE Bioscience, Inc.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on October 3, 2019)

Securities PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 2, 2019, among Pure Bioscience, Inc.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission F

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission Fil

Amendment to Consultant Agreement, effective August 1, 2019, by and between the Company and Dave Pfanzelter (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on August 2, 2018).

AMENDMENT TO CONSULTANT AGREEMENT This Amendment (this “Amendment”) to the Consultant Agreement (the “Agreement”) is entered into effective as of August 1, 2019, between PURE Bioscience, Inc.

Sublease Agreement, effective July 25, 2019, by and between the Company and SwabPlus L.P. (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the SEC on August 2, 2019).

Execution Version SUBLEASE AGREEMENT This Sublease Agreement (this “Agreement”) is made effective as of July 25, 2019 (the “Effective Date”), by and between SWABPLUS L.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission Fil

Form of Securities Purchase Agreement.

Exhibit 10.1 Securities PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 21, 2019, among Pure Bioscience, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission Fil

Consultant Agreement, dated July 8, 2019, by and between the Company and Henry R. Lambert.

Execution Version CONSULTANT AGREEMENT This CONSULTANT AGREEMENT (this “Agreement”) is entered into on July 8, 2019 by and between Pure Bioscience, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission File

Manufacturing Supply Agreement, dated June 21, 2019, by and between Pure Bioscience Inc. and Intercon Chemical Company (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on June 26, 2019).

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN EXCLUDED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. Manufacturing Supply Agreement This Manufacturing Supply Agreement (the “Agreement”), dated as of June 8, 2019 (the “Effective Date”), is entered into by and be

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission Fil

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission Fil

Form of Amendment to Securities Purchase Agreement (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the SEC on June 29, 2019).

Exhibit 10.2 PURE BIOSCIENCE, INC. AMENDMENT TO SECURITIES PURCHASE AGREEMENT This Amendment (the “Amendment”) to Securities Purchase Agreement dated May 7, 2019 (the “Agreement “) is made and entered into effective as of June 21, 2019 (the “Effective Date”), by and among Pure Bioscience, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (eac

Form of Securities Purchase Agreement.

Exhibit 10.1 Securities PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 21, 2019, among Pure Bioscience, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED November 9, 2018) PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated November 9, 2018 (the “Prospectus”), relating

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fil

PURE Bioscience Reports Fiscal 2019 Third Quarter and Nine-Month Financial Results Update on SDC-Based Antimicrobial Food Safety Solutions

PURE Bioscience Reports Fiscal 2019 Third Quarter and Nine-Month Financial Results Update on SDC-Based Antimicrobial Food Safety Solutions SAN DIEGO, CA (June 13, 2019) – PURE Bioscience, Inc.

PURE / PURE Bioscience 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission File

Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on May 13, 2019)

Securities PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 9, 2019, among Pure Bioscience, Inc.

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED November 9, 2018) PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated November 9, 2018 (the “Prospectus”), relating

PURE Bioscience Reports Fiscal 2019 Second Quarter and Six-Month Financial Results Update on SDC-Based Antimicrobial Food Safety Solutions

PURE Bioscience Reports Fiscal 2019 Second Quarter and Six-Month Financial Results Update on SDC-Based Antimicrobial Food Safety Solutions SAN DIEGO, CA (March 6, 2019) – PURE Bioscience, Inc.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fil

PURE / PURE Bioscience (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant

Form of Warrant Amendment (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on February 22, 2019)

2014 Warrant FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment (the “Amendment”) to Warrant to Purchase Common Stock (the “Warrant”), is made and entered into effective as of [], 2019 (the “Effective Date”), by and between Pure Bioscience, Inc.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2019 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

Amendment to the Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on February 1, 2019)

AMENDMENT TO BYLAWS The undersigned does hereby certify that he is the Secretary of Pure Bioscience, Inc.

PURE / PURE Bioscience DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED November 9, 2018) PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated November 9, 2018 (the “Prospectus”), relating

PURE Bioscience Reports Fiscal 2019 Q1 Financial Results Commercialization Updates on PURE Control® and PURE® Hard Surface Antimicrobial Food Safety Solutions

PURE Bioscience Reports Fiscal 2019 Q1 Financial Results Commercialization Updates on PURE Control® and PURE® Hard Surface Antimicrobial Food Safety Solutions SAN DIEGO (Dec 13, 2018) – PURE Bioscience, Inc.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2018 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE / PURE Bioscience 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus relates to the resale by selling stockholders named in this prospectus of up to 3,145,882 shares of our common stock in connection with the resale of: ● up to 1,572,941 s

PURE / PURE Bioscience POS AM

As filed with the Securities and Exchange Commission on October 25, 2018 Registration No.

PURE Bioscience Reports Fiscal 2018 Year-End Financial Results Update on PURE’s SDC-Based Antimicrobial Food Safety Solutions Outlook

PURE Bioscience Reports Fiscal 2018 Year-End Financial Results Update on PURE’s SDC-Based Antimicrobial Food Safety Solutions Outlook SAN DIEGO, CA (October 25, 2018) – PURE Bioscience, Inc.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2018 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE / PURE Bioscience 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file No. 001-14468 PURE Bioscience, Inc. (Exact

PURE Bioscience Appoints Chief Operating Officer Tom Myers Promoted to Newly Created Position

PURE Bioscience Appoints Chief Operating Officer Tom Myers Promoted to Newly Created Position SAN DIEGO, CA (October 5, 2018) – PURE Bioscience, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2018 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission F

Second Amendment to Employment Agreement, dated September 5, 2018, by and between the Company and Henry R. Lambert (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on September 7, 2018)

EXECUTION VERSION SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This SECOND AMENDMENT (the “Amendment”) to Employment Agreement, effective as of October 23, 2013, as amended effective January 19, 2017 (as amended, the “Agreement”), is made and entered into effective as of September 5, 2018 (the “Effective Date”), by and between PURE BIOSCIENCE, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2018 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2018 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or Other Jurisdiction of Incorporation) (Commission F

PURE Bioscience Closes on $1.5 Million Financing and Provides Business Update

PURE Bioscience Closes on $1.5 Million Financing and Provides Business Update SAN DIEGO, CA (Aug. 16, 2018) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that it has closed on an approximately $1.5 million private placement with existing shareholders. The $1.5 million the company raised includes cancelled ind

Consulting Agreement, dated August 13, 2018, by and between the Company and Dave Pfanzelter (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the SEC on August 7, 2018)

Execution Version CONSULTANT AGREEMENT This CONSULTING AGREEMENT (the “Agreement”) is entered into effective as of August 13, 2018 (the “Effective Date”), by and between Pure Bioscience, Inc.

Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on August 17, 2018)

Securities PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 16, 2018, among Pure Bioscience, Inc.

Consulting Agreement, dated June 28, 2018, by and between the Company and William Otis (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the SEC on July 2, 2018)

CONSULTING AGREEMENT This Agreement is made as of June 28, 2018 (the “Effective Date”), between PURE Bioscience, Inc.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2018 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission File

PURE Bioscience Raises $500,000 in Unsecured Promissory Note - Appoints Ivan Chen to Board of Directors

PURE Bioscience Raises $500,000 in Unsecured Promissory Note - Appoints Ivan Chen to Board of Directors SAN DIEGO, CA (July 2, 2018) – PURE Bioscience, Inc.

Promissory Note, dated June 28, 2018, issued to Tom Y. Lee (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on July 2, 2018)

PROMISSORY NOTE $500,000.00 June 28, 2018 FOR VALUE RECEIVED, Pure Bioscience, Inc., a Delaware corporation (the “Company), hereby promises to pay Tom Y. Lee (the “Lender”), the principal sum of Five Hundred Thousand Dollars ($500,000), together with interest thereon from the date of this Note. Interest shall accrue at a rate of 6.5% per annum, compounded annually. The principal and accrued intere

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED December 20, 2017) PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated December 20, 2017 (the “Prospectus”), relatin

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2018 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fil

PURE Bioscience Reports Fiscal 2018 Third Quarter and Nine-Month Financial Results Update on PURE’s Food Safety Solutions Outlook for Calendar 2018

PURE Bioscience Reports Fiscal 2018 Third Quarter and Nine-Month Financial Results Update on PURE’s Food Safety Solutions Outlook for Calendar 2018 SAN DIEGO, CA (June 13, 2018) – PURE Bioscience, Inc.

PURE / PURE Bioscience 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant as

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED December 20, 2017) PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated December 20, 2017 (the “Prospectus”), relatin

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2018 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission Fi

PURE Bioscience Reports Fiscal 2018 Second Quarter and Six-Month Financial Results Update on PURE’s Food Safety Solutions Outlook for Calendar 2018

PURE Bioscience Reports Fiscal 2018 Second Quarter and Six-Month Financial Results Update on PURE’s Food Safety Solutions Outlook for Calendar 2018 SAN DIEGO, CA (March 14, 2016) – PURE Bioscience, Inc.

PURE / PURE Bioscience 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2018 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

AMENDMENT TO STOCK option AGREEMENTS

AMENDMENT TO STOCK option AGREEMENTS THIS AMENDMENT TO STOCK OPTION AGREEMENT (this ?Amendment?) is made as of the 26th day of February, 2018 by and between PURE Bioscience, Inc.

PURE / PURE Bioscience

As filed with the Securities and Exchange Commission on February 26, 2018 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2018 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE BIOSCIENCE, INC. 2017 EQUITY INCENTIVE PLAN

PURE BIOSCIENCE, INC. 2017 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility; ? to provide incentives to individuals who perform services for the Company; ? to align the interests of our personnel with the interests of our stockholders; and ? to promote the success of the Co

Pledge Agreement, dated December 29, 2017, by and between Plum Investments, L.P. and Franchise Brands, LLC.

PLEDGE AGREEMENT This PLEDGE AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), made as of December 29, 2017, by and between Plum Investments, L.

PURE / PURE Bioscience / Lee Tom Y Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. )* PURE BIOSCIENCE, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 74621T209 (CUSIP Number) Tom Y. Lee c/o Plum Investments, L.P. 1807 San Gabriel Blvd. San Gabriel, CA 91776 (Name, Address and Telephone Number of Person Authorized to Receive Notices and

Guaranty of Tom Y. Lee, dated December 29, 2017, given in favor of Franchise Brands, LLC.

GUARANTY This Guaranty (as amended, restated, supplemented or otherwise modified from time to time, this “Guaranty”), dated as of December 29, 2017, is made by Tom Y.

Securities Transfer Agreement, dated December 29, 2017, by and between Plum Investments, L.P. and Franchise Brands, LLC.

SECURITIES TRANSFER AGREEMENT THIS SECURITIES TRANSFER AGREEMENT (“Agreement”), dated as of December 29, 2017, is made by and between Franchise Brands, LLC, a Delaware limited liability company (“Seller”), and Plum Investments, L.

PURE / PURE Bioscience / Franchise Brands, LLC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. 2)* PURE BIOSCIENCE, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 74621T209 (CUSIP Number) Rosa Balestrino Franchise World Headquarters, LLC 325 Sub Way, Milford, CT 06461 (203) 877-4281 (Name, Address and Telephone Number of Person Authorized to Recei

Securities Transfer Agreement, dated December 29, 2017, by and between Plum Investments, L.P. and Franchise Brands, LLC.

SECURITIES TRANSFER AGREEMENT THIS SECURITIES TRANSFER AGREEMENT (“Agreement”), dated as of December 29, 2017, is made by and between Franchise Brands, LLC, a Delaware limited liability company (“Seller”), and Plum Investments, L.

Pledge Agreement, dated December 29, 2017, by and between Plum Investments, L.P. and Franchise Brands, LLC.

PLEDGE AGREEMENT This PLEDGE AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), made as of December 29, 2017, by and between Plum Investments, L.

Guaranty of Tom Y. Lee, dated December 29, 2017, given in favor of Franchise Brands, LLC.

GUARANTY This Guaranty (as amended, restated, supplemented or otherwise modified from time to time, this “Guaranty”), dated as of December 29, 2017, is made by Tom Y.

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED December 20, 2017) PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus supplement (the ?Prospectus Supplement?) supplements our prospectus dated December 20, 2017 (the ?Prospectus?), relatin

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 176,471 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus relates to the resale by selling stockholders named in this prospectus of up to 1,749,412 shares of our common stock in connection with the resale of: ? up to 1,572,941 s

PURE Bioscience Reports Fiscal 2018 Q1 Financial Results Commercialization Updates on PURE Control® and PURE® Hard Surface Antimicrobial Food Safety Solutions

PURE Bioscience Reports Fiscal 2018 Q1 Financial Results Commercialization Updates on PURE Control? and PURE? Hard Surface Antimicrobial Food Safety Solutions SAN DIEGO (Dec.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2017 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE / PURE Bioscience 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Commission File Number 001-14468 PURE Bioscience, Inc. (Exact name of registrant

PURE / PURE Bioscience 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

PURE / PURE Bioscience 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

PURE Bioscience Expands Board of Directors with Appointment of Elisabeth Hagen, M.D., Food Safety Consultant

PURE Bioscience Expands Board of Directors with Appointment of Elisabeth Hagen, M.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2017 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction (Commission (IRS Employer of i

As filed with the Securities and Exchange Commission on October 27, 2017

As filed with the Securities and Exchange Commission on October 27, 2017 Registration No.

PURE / PURE Bioscience 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file No. 001-14468 PURE Bioscience, Inc. (Exact

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2017 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE Bioscience Reports Fiscal 2017 Year-End Financial Results Commercialization Updates on PURE Control® and PURE® Hard Surface Antimicrobial Food Safety Solutions

PURE Bioscience Reports Fiscal 2017 Year-End Financial Results Commercialization Updates on PURE Control? and PURE? Hard Surface Antimicrobial Food Safety Solutions SAN DIEGO (Oct.

PURE Bioscience O-I/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A (Amendment No. 3) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 PURE BIOSCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 74621T209 (CUSIP Number of Common Stock Underlyin

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2017 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission

PURE Bioscience Completes Successful Warrant Tender Offer and Raises $2.8 Million from Exercise of Warrants

PURE Bioscience Completes Successful Warrant Tender Offer and Raises $2.8 Million from Exercise of Warrants SAN DIEGO (October 12, 2017) ? PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on October 10, 2017 it successfully completed a tender offer to amend and exercise three classes of outstanding warrants

Notice of Approval of Aggregate Warrant Amendment Offer

Exhibit (a)(1)(E) September 26, 2017 NOTICE OF APPROVAL OF AGGREGATE WARRANT AMENDMENT OFFER To the Holders of the 2014, 2015 and 2017 Warrants: Pure Bioscience, Inc.

PURE Bioscience O-I/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 PURE BIOSCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 74621T209 (CUSIP Number of Common Stock Underlyin

PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 1,572,941 shares of Common Stock issuable upon the exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration File No. 333-215915 PROSPECTUS PURE BIOSCIENCE, INC. 1,572,941 shares of Common Stock 1,572,941 shares of Common Stock issuable upon the exercise of Outstanding Warrants This prospectus relates to the resale by selling stockholders named in this prospectus of up to 3,145,882 shares of our common stock in connection with the resale of: ? up to 1,572,941

PURE Bioscience O-I/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 PURE BIOSCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 74621T209 (CUSIP Number of Common Stock Underlyin

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2017 PURE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-14468 33-0530289 (State or other jurisdiction of incorporation) (Commission F

Form of Amendment and Waiver, dated August 23, 2017, by and between the Company and that certain holder party thereto (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on August 25, 2017)

PURE BIOSCIENCE, INC. AMENDMENT AND WAIVER August 23, 2017 This Amendment and Waiver (this ?Amendment and Waiver?) to that certain Securities Purchase Agreement (the ?Securities Purchase Agreement?) and Registration Rights Agreement (the ?Registration Rights Agreement?), each dated as of December 1, 2016, entered into between Pure Bioscience, Inc. and the Purchasers thereto (the ?Purchasers?) is e

Form of 2014 Amended Warrant

Exhibit (a)(1)(F) 2014 Warrant FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment (the ?Amendment?) to Warrant to Purchase Common Stock (the ?Warrant?), is made and entered into effective as of [], 2017 (the ?Effective Date?), by and between Pure Bioscience, Inc.

Form of 2015 Amended Warrant

Exhibit (a)(1)(G) 2015 Warrant FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment (the ?Amendment?) to Warrant to Purchase Common Stock (the ?Warrant?), is made and entered into effective as of [], 2017 (the ?Effective Date?), by and between Pure Bioscience, Inc.

Form of Notice of Withdrawal

Exhibit (a)(1)(D) NOTICE OF WITHDRAWAL OF EXERCISE OF WARRANTS PURSUANT TO THE OFFER TO AMEND AND EXERCISE WARRANTS TO PURCHASE COMMON STOCK DATED AUGUST 25, 2017 THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 5:00 P.

Letter to Holders of Original Warrants

Exhibit (a)(1)(A) August 25, 2017 PURE BIOSCIENCE, INC. 1725 Gillespie Way El Cajon, California 92020 To the Holders of the Warrants: This letter is to inform you that Pure Bioscience, Inc. (the “Company”) is offering to amend, upon the terms and subject to the conditions set forth in the enclosed Offer to Amend and Exercise Warrants to Purchase Common Stock, warrants to purchase an aggregate of 7

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 PURE BIOSCIENCE, INC. (Name of Subject Company (Issuer) and Filing Pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 PURE BIOSCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 74621T209 (CUSIP Number of Common Stock Underlying Warrants) Henry R.

Power of Attorney (incorporated by reference to the signature page to the Post-Effective Amendment No. 1 to Registration Statement filed on August 25, 2017)

As filed with the Securities and Exchange Commission on August 25, 2017 Registration No.

Form of Notice of Approval of Aggregate Warrant Amendment Offer

Exhibit (a)(1)(E) [], 2017 [FORM OF NOTICE] OF APPROVAL OF AGGREGATE WARRANT AMENDMENT OFFER To the Holders of the [2014, 2015 and/or 2017 Warrants]: Pure Bioscience, Inc.

Form of 2017 Amended Warrant

Exhibit (a)(1)(H) 2017 Warrant FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment (the ?Amendment?) to Warrant to Purchase Common Stock (the ?Warrant?), is made and entered into effective as of [], 2017 (the ?Effective Date?), by and between Pure Bioscience, Inc.

(3)* Engagement Agreement, dated as of August 21, 2017, by and between the Company and Garden State Securities Inc.

Garden State Securities Inc. 328 Newman Springs Rd. Red Bank, NJ 07707 August 21, 2017 PURE Bioscience, Inc. 1725 Gillespie Way El Cajon, California 92020 ATT: Henry R. Lambert, Chief Executive Officer Re: Engagement Agreement Amendment for Warrant Exercise Dear Mr. Lambert, This letter sets forth changes to our Letter Agreement executed May 12, 2016 by and among PURE Biosciences, Inc. and its sub

Form of Election to Participate and Exercise Warrant and Approve Aggregate Warrant Amendment Offer

Exhibit (a)(1)(C) ELECTION TO PARTICIPATE AND EXERCISE WARRANTS PURSUANT TO OFFER TO AMEND AND EXERCISE COMMON STOCK OF PURE BIOSCIENCE, INC.

Offer to Amend and Exercise

Exhibit (a)(1)(B) NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE TRANSACTION CONTEMPLATED HEREIN; PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION; OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS DOCUMENT.

PURE Bioscience

As filed with the Securities and Exchange Commission on August 23, 2017 Registration No.